- Home
- UNCY vs CBUS Comparison
UNCY vs CBUS Comparison
Compare UNCY & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CBUS
- Stock Information
- Founded
- UNCY 2016
- CBUS 2010
- Country
- UNCY United States
- CBUS United States
- Employees
- UNCY N/A
- CBUS N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- UNCY Health Care
- CBUS Industrials
- Exchange
- UNCY Nasdaq
- CBUS Nasdaq
- Market Cap
- UNCY 74.2M
- CBUS 72.0M
- IPO Year
- UNCY 2021
- CBUS 2017
- Fundamental
- Price
- UNCY $4.93
- CBUS $1.71
- Analyst Decision
- UNCY Strong Buy
- CBUS Strong Buy
- Analyst Count
- UNCY 5
- CBUS 2
- Target Price
- UNCY $55.20
- CBUS $21.25
- AVG Volume (30 Days)
- UNCY 419.1K
- CBUS 763.3K
- Earning Date
- UNCY 11-12-2025
- CBUS 11-06-2025
- Dividend Yield
- UNCY N/A
- CBUS N/A
- EPS Growth
- UNCY N/A
- CBUS N/A
- EPS
- UNCY N/A
- CBUS N/A
- Revenue
- UNCY N/A
- CBUS $4,846,000.00
- Revenue This Year
- UNCY N/A
- CBUS $17.67
- Revenue Next Year
- UNCY $19,912.34
- CBUS $63.43
- P/E Ratio
- UNCY N/A
- CBUS N/A
- Revenue Growth
- UNCY N/A
- CBUS 63.66
- 52 Week Low
- UNCY $3.71
- CBUS $1.20
- 52 Week High
- UNCY $11.00
- CBUS $6.10
- Technical
- Relative Strength Index (RSI)
- UNCY 66.90
- CBUS 68.84
- Support Level
- UNCY $4.33
- CBUS $1.36
- Resistance Level
- UNCY $4.81
- CBUS $1.99
- Average True Range (ATR)
- UNCY 0.31
- CBUS 0.12
- MACD
- UNCY 0.04
- CBUS 0.03
- Stochastic Oscillator
- UNCY 70.07
- CBUS 61.91
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.